Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial
In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with…